Q: What need is Personal Genome Diagnostics (PGDx) addressing? A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients....
Q: What need is Clusterone addressing? A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome....
VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report....
Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI? A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the...
Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve? A: We are focused on physical resilience, or the dynamic ability to maintain or recover function following a stressor....
Q: What need is LabCorp addressing? A: The timeless issues LabCorp continues to address are those related to delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to improve the delivery of healthcare....
Q: What need is LifeOmic addressing? A: Precision Medicine requires the aggregation of huge data sets, including data representing individual patients from the level of their genomes all the way up through various levels of their phenomes....
Q: GeneCentric employs Drug Response Biomarkers developed via the Cancer Subtyping Platform (CSP). What makes your approach of biomarker development unique? A: By applying CSPTM technology, GeneCentric is developing universal drug response biomarkers to enable more effective and efficient drug development informed by high resolution,...
Q: What need is Precision BioSciences addressing? A: Precision’s ARCUS genome editing technology is a proprietary, non-CRIPSR platform that has applications across cell therapy, gene therapy, and agriculture. We are able to edit everything from plants to primates, so prioritizing projects is an imporant part...
Q: Why is preemptive pharmacogenetics testing important in the context of personalized medicine? A: We estimated that pharmacogenetic test results can impact the use of nearly 100 drugs, accounting for up to 18% of current prescriptions. Therefore, having pharmacogenetic test results already “in hand” at the...
